Woman’s cancer diagnosis after attributing symptoms to weight‑loss injection prompts warning from clinicians

A 52-year-old woman in Lancashire who initially attributed chest pain and other symptoms to a prescription weight‑loss injection has been diagnosed with terminal soft‑tissue sarcoma, prompting clinicians to warn that some cancer signs can be mistaken for common side effects of GLP‑1 drugs.

Dawn Clegg was prescribed tirzepatide, sold under the brand name Mounjaro, to treat type 2 diabetes. Mounjaro and other GLP‑1 receptor agonists work by increasing insulin secretion when needed, reducing liver glucose production and slowing digestion, and are known to cause gastrointestinal side effects such as nausea, indigestion, constipation and diarrhoea. Clegg told reporters she first experienced chest pain in March and assumed it was a side effect of the medication. When the pain persisted she attended an emergency department; X‑rays and further imaging revealed masses on her lungs, kidneys and breast. She was told the lung growth was malignant and was formally diagnosed with soft‑tissue sarcoma and given a prognosis of less than a year to live.

Soft‑tissue sarcoma is a rare and often aggressive cancer that can arise in muscles, fat, blood vessels, ligaments and tendons. There are more than 100 recognised subtypes, and in the United Kingdom the disease is estimated to affect roughly 5,300 people a year. While a painless lump is the most common symptom, other manifestations such as abdominal pain, constipation or unexplained fullness can overlap with the known gastrointestinal effects of GLP‑1 weight‑loss injections.

"As a clinician, hearing about cases like this is always sobering," said Dr. Jack Ogden, an NHS general practitioner at The Lagmon Clinic. "It reinforces how easy it is for both patients and healthcare professionals to attribute symptoms to the most obvious cause, in this case weight‑loss injections, when something more serious may be underlying." He and other clinicians emphasised the importance of monitoring persistent symptoms and seeking medical assessment rather than assuming new problems are medication side effects.

Public health specialists and pharmacists highlighted other instances in which cancer signs were initially attributed to GLP‑1 drugs. One account involved a patient who experienced persistent fatigue, nausea and early satiety while on a GLP‑1 medication; subsequent investigation by their general practitioner revealed stage two stomach cancer. Ana Carolina Gonclaves, a superintendent pharmacist, warned that indigestion, heartburn and abdominal pain — common with the injections — can also be symptoms of liver, bladder, pancreatic or stomach cancer. "Given the increasing use of weight‑loss injections in the UK, the potential for confusion is likely growing, especially for cancer symptoms that overlap with common injection side effects," she said.

Manufacturers of GLP‑1 products already list certain potential cancer risks in safety communications. Eli Lilly, the maker of Mounjaro, has previously cautioned that the drug may cause tumours in the thyroid in rodent studies and advised users to watch for possible symptoms such as a lump or swelling in the neck. Novo Nordisk, which produces Wegovy, lists thyroid tumours as a potential adverse effect in its product information.

Kevin Joshua, clinical lead at Juniper, a provider of weight‑loss medications, said the concern is that persistent or worsening symptoms may be written off as "just the jab" and that lost time can be critical: "That missed time can make all the difference in cancer treatment and survival."

The issue of symptom overlap has gained attention alongside emerging observational research on cancer outcomes in people taking GLP‑1 therapies. The largest long‑term study published to date followed nearly 44,000 overweight and obese patients for up to 10 years. Investigators reported a 17 percent lower risk of cancer overall among people on the drugs, with notable reductions in some tumour types such as ovarian and uterine cancers. However, the analysis also identified a signal for increased risk of kidney cancer: patients treated with GLP‑1 drugs were about one‑third more likely to develop kidney cancer than those who did not take them, a risk that appeared higher among people under 65 and those who were overweight.

Clinicians noted that kidney cancer is often a "silent" disease until it is advanced. Red‑flag signs include blood in the urine, persistent back or flank pain and a palpable lump beneath the ribs; by the time such symptoms appear the disease is frequently more difficult to treat. In the UK, roughly 14,000 people are diagnosed with kidney cancer each year with about 4,700 deaths; in the United States, there are about 80,000 new cases annually. Survival is substantially greater when the disease is detected early: approximately three‑quarters of patients survive at least five years if the cancer is confined to the kidney, compared with about 18 percent when it has spread.

Experts stressed that there is currently no robust estimate of how often cancer symptoms are misattributed to weight‑loss injections. They advised that patients using GLP‑1 drugs keep a record of new or persistent symptoms and consult a general practitioner if symptoms do not resolve, worsen, or are accompanied by red‑flag signs such as vomiting blood, blood in the stool, jaundice, unexplained weight loss, or a new lump. Health professionals said prompt assessment may improve the chances of early diagnosis and more effective treatment.

Clegg's family said they were devastated by the diagnosis. Her husband described the difficulty of receiving the news and the uncertainty around finding an effective treatment, noting clinicians were still determining the sarcoma subtype months after the diagnosis. The case and expert warnings come as GLP‑1 therapies remain widely prescribed for diabetes and increasingly used for weight management, heightening the importance of distinguishing common drug reactions from symptoms that require urgent investigation.